Chromatin (DNA) Removal From Harvest Before an AAV Capture Step Greatly Improves Robustness, Purity, and Yield of the Overall Downstream Process

Aleš Štrancar, Managing Director, Sartorius BIA Separations


Adeno associated virus (AAV) is the leading vector in the field of gene therapy because of its low toxicity, good overall safety profile, and ability to maintain stable expression for long periods of time. It is therefore crucial to develop a robust and high efficiency platform for its manufacturing.
Therapeutic applications of AAV-based gene therapy vectors require the process and product related impurities to be removed, as they represent serious safety threats as well as burden the economics of manufacturing.

    Your Cart
    Your cart is emptyReturn to Shop
      This site is registered on as a development site. Switch to a production site key to remove this banner.